Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-07-02, Stock:PFE, The news for the past five days is as follows:
2019-06-25: NEWS1: Stocks Swing Lower As Rate Cut Optimism Dampens.NEWS2: Stocks Swing Lower As Rate Cut Optimism Dampens.NEWS3: Pfizer (PFE) Flat As Market Sinks: What You Should Know.NEWS4: 3 Healthcare Stocks to Buy With the Market Near All-Time Highs.NEWS5: 3 Healthcare Stocks to Buy With the Market Near All-Time Highs.NEWS6: After Hours Most Active for Jun 25, 2019 :  DIS, TI, LC, PFE, NEM, QD.NEWS7: After Hours Most Active for Jun 25, 2019 :  DIS, TI, LC, PFE, NEM, QD.NEWS8: Abbvie Decides to Acquire Allergan.NEWS9: Noteworthy ETF Inflows: SPY, BRK.B, DIS, PFE.NEWS10: Noteworthy ETF Inflows: SPY, BRK.B, DIS, PFE.NEWS11: AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20.NEWS12: Dow Movers: GS, JNJ.NEWS13: Dow Movers: GS, JNJ.NEWS14: Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015.NEWS15: Abbvie Decides to Acquire Allergan.NEWS16: Pfizer’s Oncology Treatment Growth Drivers.NEWS17: AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20.NEWS18: Comparing PFE’s and BMY’s Expense Trends.NEWS19: How PFE’s and BMY’s EPS Trends Compare.NEWS20: Allergan stock surges on news that Abbvie will buy Botox maker in a $63 billion deal.
2019-06-26: NEWS1: 3 Dividend Stocks That Could Pay You the Rest of Your Life.NEWS2: Conatus' Emricasan Lags Primary Goal in Liver Function Study.NEWS3: Conatus' Emricasan Lags Primary Goal in Liver Function Study.NEWS4: Comparing PFE’s and BMY’s Immunology Drugs.NEWS5: Conatus' Emricasan Lags Primary Goal in Liver Function Study.NEWS6: 3 Dividend Stocks That Could Pay You the Rest of Your Life.NEWS7: 3 Dividend Stocks That Could Pay You the Rest of Your Life.NEWS8: Pfizer (PFE) Flat As Market Sinks: What You Should Know.NEWS9: Pfizer (PFE) Flat As Market Sinks: What You Should Know.NEWS10: 3 Biopharma Stocks to Buy for Income.NEWS11: 3 Biopharma Stocks to Buy for Income.
2019-06-27: NEWS1: Pfizer names former FDA chief Scott Gottlieb to its board.NEWS2: Scott Gottlieb Elected to Pfizer’s Board of Directors.NEWS3: Pfizer Declares Third-Quarter 2019 Dividend.NEWS4: Lilly's Study on Higher Doses of Trulicity Meets Endpoint.NEWS5: Lilly's Study on Higher Doses of Trulicity Meets Endpoint.NEWS6: Draper laboratory signs 'organ-on-chip' development deal with Bristol-Myers Squibb.NEWS7: Bayer Sets Up Special Committee to Tackle Glyphosate Lawsuits.NEWS8: Bayer Sets Up Special Committee to Tackle Glyphosate Lawsuits.NEWS9: Lilly's Study on Higher Doses of Trulicity Meets Endpoint.NEWS10: Bayer Sets Up Special Committee to Tackle Glyphosate Lawsuits.NEWS11: Ex-FDA boss joins Pfizer 83 days after leaving US drug regulator.
2019-06-28: NEWS1: AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study.NEWS2: AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study.NEWS3: Here's Why Sarepta Therapeutics Is Surging Today.NEWS4: Here's Why Sarepta Therapeutics Is Surging Today.NEWS5: These Are The 5 Worst Dow Jones Stocks In The First Half Of 2019.NEWS6: AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study.NEWS7: Daily Dividend Report: FNLC, PFE, T, NYT, BFS.NEWS8: Daily Dividend Report: FNLC, PFE, T, NYT, BFS.NEWS9: After Hours Most Active for Jun 27, 2019 :  CZR, UBER, PFE, SYF, AAPL, TRUE, MU, VEON, BAC, NKE, KO, QCOM.NEWS10: After Hours Most Active for Jun 27, 2019 :  CZR, UBER, PFE, SYF, AAPL, TRUE, MU, VEON, BAC, NKE, KO, QCOM.NEWS11: Gene Therapy Battle: Pfizer's Test Results Sent This Biotech Stock Flying.NEWS12: Here&apos;s Why Sarepta Therapeutics Is Surging Today.NEWS13: Pfizer Announces Results from Phase 3 Trial of Revatio® (Sildenafil Citrate) in Newborns with Persistent Pulmonary Hypertension.NEWS14: Sarepta Therapeutics Soars as Pfizer's Competing Drug Shows Safety Problems.NEWS15: Street Crowns Sarepta DMD Gene Therapy King After Pfizer Results.NEWS16: Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger.NEWS17: Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger.NEWS18: Dow 30 Stock Roundup: Nike Earnings Disappoint, Walgreens Boots Margins Drop.NEWS19: Dow 30 Stock Roundup: Nike Earnings Disappoint, Walgreens Boots Margins Drop.NEWS20: Sarepta surges after Pfizer gene therapy data raises safety concerns.NEWS21: Pfizer gene therapy for rare muscle disease shows promise in small, early study.NEWS22: Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD).NEWS23: Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger.NEWS24: Can Roche's #1 Therapeutic Area With $28 Billion In Revenue Grow Further?.NEWS25: Can Roche's #1 Therapeutic Area With $28 Billion In Revenue Grow Further?.NEWS26: Dow 30 Stock Roundup: Nike Earnings Disappoint, Walgreens Boots Margins Drop.NEWS27: Pfizer's Avastin biosimilar wins FDA approval.NEWS28: Pfizer says FDA has approved its oncology biosimilar Zirabev to treat 5 types of cancer.NEWS29: Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr).NEWS30: The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO.
2019-07-01: NEWS1: After Hours Most Active for Jul 1, 2019 :  BX, KO, VZ, BAC, PFE, ET.NEWS2: After Hours Most Active for Jul 1, 2019 :  BX, KO, VZ, BAC, PFE, ET.NEWS3: S&P 500 settles below intraday high sparked by U.S.-China trade truce.NEWS4: S&P 500 eases off intraday high sparked by U.S.- China trade truce.NEWS5: The Zacks Analyst Blog Highlights: NIKE, Walgreens Boots Alliance, UnitedHealth, Pfizer and Home Depot.NEWS6: The Zacks Analyst Blog Highlights: NIKE, Walgreens Boots Alliance, UnitedHealth, Pfizer and Home Depot.NEWS7: Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study.NEWS8: Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study.NEWS9: Company News for Jul 1, 2019.NEWS10: Company News for Jul 1, 2019.NEWS11: Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues.NEWS12: Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues.NEWS13: Pfizer's (PFE) Avastin Biosimilar Zirabev Gets FDA Approval.NEWS14: Pfizer's (PFE) Avastin Biosimilar Zirabev Gets FDA Approval.NEWS15: Acquisition Improves the Outlook of Pfizer Stock.NEWS16: Acquisition Improves the Outlook of Pfizer Stock.NEWS17: The Zacks Analyst Blog Highlights: NIKE, Walgreens Boots Alliance, UnitedHealth, Pfizer and Home Depot.NEWS18: Sarepta Therapeutics Stock Could Capitalize From Pfizer’s Stumble.NEWS19: Pfizer Completes Acquisition of Therachon.NEWS20: Health Care Sector Update for 07/01/2019: TLSA, BCYC, CERC, JNJ, PFE, ABT, MRK, AMGN.NEWS21: Health Care Sector Update for 07/01/2019: TLSA, BCYC, CERC, JNJ, PFE, ABT, MRK, AMGN.NEWS22: Pfizer's (PFE) Avastin Biosimilar Zirabev Gets FDA Approval.NEWS23: Futures soar after Trump, Xi agree to hold off on new tariffs.NEWS24: Pfizer Gains on Positive Children-Dermatitis Treatment Results.NEWS25: Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues.NEWS26: Company News for Jul 1, 2019.NEWS27: Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study.NEWS28: Pfizer stock up 1.2% premarket after drugmaker announces positive results from Phase 4 eczema study.NEWS29: Pfizer Announces Positive Top-Line Results from Phase 4 Study of Crisaborole Ointment, 2%, in Children Aged 3 Months to Less Than 24 Months with Mild to Moderate Atopic Dermatitis.NEWS30: Acquisition Improves the Outlook of Pfizer Stock.

Answer: Rise